U.S. markets closed

Synairgen plc (SNG.L)

LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
165.000.00 (0.00%)
At close: 5:07PM BST

Synairgen plc

Mailpoint 810
Level F, South Block Southampton General Hospital Tremona Road
Southampton SO16 6YD
United Kingdom
44 23 8051 2800
http://www.synairgen.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees14

Key Executives

NameTitlePayExercisedYear Born
Mr. Richard MarsdenCEO, MD & Exec. Director289kN/A1968
Mr. John WardFin. Director, Company Sec. & Exec. Director226kN/A1962
Dr. Phillip David MonkChairman of Scientific Advisory Board, Chief Scientific Officer & Exec. Director208kN/A1969
Prof. Donna DaviesCo-Founder & Member of Scientific Advisory BoardN/AN/AN/A
Prof. Ratko DjukanovicCo-Founder & Member of Scientific Advisory BoardN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.

Description

Synairgen plc discovers and develops drugs for respiratory diseases. It develops inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; IFN-ß that is in Phase-II clinical trial for the treatment or prevention of chronic obstructive pulmonary disease exacerbations caused by the common cold and flu; and LOXL2 inhibitor, which has completed Phase I clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF) and non-alcoholic fatty liver diseases. The company has a licensing and collaboration agreement with Pharmaxis Ltd. to develop a LOXL2 inhibitor. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.

Corporate Governance

Synairgen plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.